KATELYN HEIST: Open Payments
NPI 1831827609 · DUNKIRK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$812 in 41 payments from 19 companies in 2025. Trend: 2023 $604 · 2024 $1,095 · 2025 $812
Food & beverage: $812
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $130 |
| Novo Nordisk Inc | 5 | $112 |
| PFIZER INC. | 5 | $109 |
| Amgen Inc. | 4 | $65 |
| Lilly USA, LLC | 2 | $46 |
| Exact Sciences Corporation | 2 | $46 |
| Insulet Corporation | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
Products named: TRELEGY ELLIPTA, OTEZLA, MOUNJARO, PREVNAR 20, Omnipod, XIFAXAN, CAPLYTA, Veozah.
Industry payments across NY — which companies pay providers there.
